Suzhou is a national famous historic and cultural city and a scenic-tourist city. As the National High & New Technology Industry Base, it is one of the important cities in the city cluster of Yangtze River Delta. By the end of 2016, 150 Fortune 500 Companies have had invested projects (enterprises) in Suzhou. Compared with 2015, there is higher growth of total production value of biotechnology and new medical industry and fixed assets investment. For the past decades, Suzhou Biomedical Industrial Park has linked the assets, talents and science & technology, etc. together, trying to build up a best biomedical industry eco-sphere around the world with a sense of focusing, joint-efforts and innovation. Now over 460 enterprises have been settled here and formed a characteristic industrial cluster, including new medicine development, medical apparatus and instruments (including in vitro diagnosis), biotechnology etc. For biomedical field, the park introduced a batch of international major innovative organizations, like Suzhou advanced research center of Oxford University and sets up a group of important international cooperation platforms, including “China-Singapore (Suzhou) Innovative Center”, “China-Israel (Suzhou) Big Health Innovative Center”. In June, 2017, the opening ceremony of Suzhou biomedical industry park Phase II was held to undertake industrialization base. At present, these enterprises started their business in Zone A, like Roche Group, BeiGene, ZAI Lab, Beckman Coulter. These enterprises signed agreement and settled in Zone B, like Tianhao, Cure Genetics etc. Zone C shall start to be built in the end of 2017.